Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
Advanced Solid Tumor|MSI-H/dMMR Tumors|Cutaneous Squamous Cell Carcinoma|Urothelial Carcinoma|Cervical Cancer|HepatoCellular Carcinoma|Esophageal Squamous Cell Carcinoma|Merkel Cell Carcinoma|Small-cell Lung Cancer|Mesothelioma|PD-L1 Amplified Tumor (9p24.1)|Nasopharyngeal Carcinoma
DRUG: INCB099280
Number of treatment-emergent adverse events, Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug up to 30 days after last dose of study drug., Up to approximately 25 months
Cmax of INCB099280, Maximum observed plasma concentration, Up to approximately 3 months|tmax of INCB099280, Time to maximum plasma concentration, Up to approximately 3 months|Cmin of INCB099280, Minimum observed plasma concentration over the dose interval, Up to approximately 3 months|AUC0-t of INCB099280, Area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t, Up to approximately 3 months|t½ of INCB099280, Apparent terminal-phase disposition half-life, Up to approximately 3 months|λz of INCB099280, Terminal elimination rate constant, Up to approximately 3 months|CL/F of INCB099280, Oral dose clearance, Up to approximately 3 months|Vz/F of INCB099280, Apparent oral dose volume of distribution, Up to approximately 3 months
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors